Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lucid Diagnostics (Nasdaq: LUCD) has successfully regained compliance with Nasdaq's minimum bid price requirement, the company announced on February 25, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) has successfully regained compliance with Nasdaq's minimum bid price requirement, the company announced on February 25, 2025. The commercial-stage cancer prevention medical diagnostics company, a subsidiary of PAVmed Inc. (Nasdaq: PAVM), had previously been notified of non-compliance for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
To resolve this issue, Lucid was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days, a condition that was satisfied on February 21, 2025. Following this achievement, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "LUCD".
Positive
- Regained Nasdaq compliance, avoiding potential delisting
Negative
- Previously failed to maintain minimum stock price requirements
Details
News Market Reaction – LUCD
The recorded move for LUCD in the trading session of this news was +2.16%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
As previously disclosed, the Company was notified by Nasdaq that it was not in compliance with this listing rule because it failed to maintain a minimum closing bid price of its common stock of
The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "LUCD".
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302384434.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.